278 related articles for article (PubMed ID: 35585884)
1. Empagliflozin Ameliorates Diabetic Cardiomyopathy via Attenuating Oxidative Stress and Improving Mitochondrial Function.
Wang J; Huang X; Liu H; Chen Y; Li P; Liu L; Li J; Ren Y; Huang J; Xiong E; Tian Z; Dai X
Oxid Med Cell Longev; 2022; 2022():1122494. PubMed ID: 35585884
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice.
Xue M; Li T; Wang Y; Chang Y; Cheng Y; Lu Y; Liu X; Xu L; Li X; Yu X; Sun B; Chen L
Clin Sci (Lond); 2019 Aug; 133(15):1705-1720. PubMed ID: 31337673
[TBL] [Abstract][Full Text] [Related]
3. Empagliflozin attenuates arrhythmogenesis in diabetic cardiomyopathy by normalizing intracellular Ca
Kadosaka T; Watanabe M; Natsui H; Koizumi T; Nakao M; Koya T; Hagiwara H; Kamada R; Temma T; Karube F; Fujiyama F; Anzai T
Am J Physiol Heart Circ Physiol; 2023 Mar; 324(3):H341-H354. PubMed ID: 36607794
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
Li C; Zhang J; Xue M; Li X; Han F; Liu X; Xu L; Lu Y; Cheng Y; Li T; Yu X; Sun B; Chen L
Cardiovasc Diabetol; 2019 Feb; 18(1):15. PubMed ID: 30710997
[TBL] [Abstract][Full Text] [Related]
5. SGLT2 inhibitor-empagliflozin treatment ameliorates diabetic retinopathy manifestations and exerts protective effects associated with augmenting branched chain amino acids catabolism and transportation in db/db mice.
Gong Q; Zhang R; Wei F; Fang J; Zhang J; Sun J; Sun Q; Wang H
Biomed Pharmacother; 2022 Aug; 152():113222. PubMed ID: 35671581
[TBL] [Abstract][Full Text] [Related]
6. The Sodium-Glucose Co-Transporter 2 Inhibitor, Empagliflozin, Protects against Diabetic Cardiomyopathy by Inhibition of the Endoplasmic Reticulum Stress Pathway.
Zhou Y; Wu W
Cell Physiol Biochem; 2017; 41(6):2503-2512. PubMed ID: 28472796
[TBL] [Abstract][Full Text] [Related]
7. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
[TBL] [Abstract][Full Text] [Related]
8. FNDC5/Irisin attenuates diabetic cardiomyopathy in a type 2 diabetes mouse model by activation of integrin αV/β5-AKT signaling and reduction of oxidative/nitrosative stress.
Lin C; Guo Y; Xia Y; Li C; Xu X; Qi T; Zhang F; Fan M; Hu G; Zhao H; Zhao H; Liu R; Gao E; Yan W; Tao L
J Mol Cell Cardiol; 2021 Nov; 160():27-41. PubMed ID: 34224725
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin improves mitochondrial dysfunction in diabetic cardiomyopathy by modulating ketone body metabolism and oxidative stress.
Cai W; Chong K; Huang Y; Huang C; Yin L
Redox Biol; 2024 Feb; 69():103010. PubMed ID: 38160540
[TBL] [Abstract][Full Text] [Related]
10. Empagliflozin prohibits high-fructose diet-induced cardiac dysfunction in rats via attenuation of mitochondria-driven oxidative stress.
Bugga P; Mohammed SA; Alam MJ; Katare P; Meghwani H; Maulik SK; Arava S; Banerjee SK
Life Sci; 2022 Oct; 307():120862. PubMed ID: 35934058
[TBL] [Abstract][Full Text] [Related]
11. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes.
Habibi J; Aroor AR; Sowers JR; Jia G; Hayden MR; Garro M; Barron B; Mayoux E; Rector RS; Whaley-Connell A; DeMarco VG
Cardiovasc Diabetol; 2017 Jan; 16(1):9. PubMed ID: 28086951
[TBL] [Abstract][Full Text] [Related]
12. Empagliflozin ameliorates vascular calcification in diabetic mice through inhibiting Bhlhe40-dependent NLRP3 inflammasome activation.
Li XX; Chen ZD; Sun XJ; Yang YQ; Jin H; Liu NF
Acta Pharmacol Sin; 2024 Apr; 45(4):751-764. PubMed ID: 38172306
[TBL] [Abstract][Full Text] [Related]
13. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
Yurista SR; Silljé HHW; Oberdorf-Maass SU; Schouten EM; Pavez Giani MG; Hillebrands JL; van Goor H; van Veldhuisen DJ; de Boer RA; Westenbrink BD
Eur J Heart Fail; 2019 Jul; 21(7):862-873. PubMed ID: 31033127
[TBL] [Abstract][Full Text] [Related]
14. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor Ameliorate Metabolic Disorder and Obesity Induced Cardiomyocyte Injury and Mitochondrial Remodeling.
Jhuo SJ; Lin YH; Liu IH; Lin TH; Wu BN; Lee KT; Lai WT
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047815
[TBL] [Abstract][Full Text] [Related]
15. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin inhibits excessive autophagy through the AMPK/GSK3β signalling pathway in diabetic cardiomyopathy.
Madonna R; Moscato S; Cufaro MC; Pieragostino D; Mattii L; Del Boccio P; Ghelardoni S; Zucchi R; De Caterina R
Cardiovasc Res; 2023 May; 119(5):1175-1189. PubMed ID: 36627733
[TBL] [Abstract][Full Text] [Related]
17. Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts.
Mizuno M; Kuno A; Yano T; Miki T; Oshima H; Sato T; Nakata K; Kimura Y; Tanno M; Miura T
Physiol Rep; 2018 Jun; 6(12):e13741. PubMed ID: 29932506
[TBL] [Abstract][Full Text] [Related]
18. RTA 408 ameliorates diabetic cardiomyopathy by activating Nrf2 to regulate mitochondrial fission and fusion and inhibiting NF-κB-mediated inflammation.
Hao J; Zhou J; Hu S; Zhang P; Wu H; Yang J; Zhao B; Liu H; Lin H; Chi J; Lou D
Am J Physiol Cell Physiol; 2024 Feb; 326(2):C331-C347. PubMed ID: 38047307
[TBL] [Abstract][Full Text] [Related]
19. Moderate intensity exercise prevents diabetic cardiomyopathy associated contractile dysfunction through restoration of mitochondrial function and connexin 43 levels in db/db mice.
Veeranki S; Givvimani S; Kundu S; Metreveli N; Pushpakumar S; Tyagi SC
J Mol Cell Cardiol; 2016 Mar; 92():163-173. PubMed ID: 26827898
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin ameliorates diabetic cardiomyopathy probably
Li N; Zhu QX; Li GZ; Wang T; Zhou H
World J Diabetes; 2023 Dec; 14(12):1862-1876. PubMed ID: 38222788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
